Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE
1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.
• Aged from 18 to 80 years;
• Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.;
• First stroke onset ≥ 1 month and ≤ 3 months;
• mRS Score \<=2 points;
• Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days;
• Informed consent signed by the patient or their family member.